Quick Answer
MiNK Therapeutics, Inc. reported Stockholders Equity of -$14.23 million for fiscal year 2025.
MiNK Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | -$14.23M | +27.4% |
| 2024 | -$19.59M | -8.5% |
| 2023 | -$18.06M | -4399.2% |
| 2022 | -$401.3K | -101.7% |
| 2021 | $23.78M | +144.1% |
| 2020 | -$53.87M | -48.3% |
| 2019 | -$36.33M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$13.51M | +23.0% | +46.4% |
| June 30, 2025 | -$25.19M | -52.0% | -15.6% |
| March 31, 2025 | -$21.79M | -7.4% | -11.3% |
| December 31, 2024 | -$19.59M | -8.5% | -11.6% |
| September 30, 2024 | -$17.55M | -29.3% | -5.9% |
| June 30, 2024 | -$16.58M | -74.6% | +18.3% |
| March 31, 2024 | -$20.30M | -353.5% | -12.4% |
| December 31, 2023 | -$18.06M | -4399.2% | -32.9% |
- MiNK Therapeutics, Inc. showed an increase of +27.4% in Stockholders Equity compared to the prior fiscal year.
- Over the 2019–2025 period, MiNK Therapeutics, Inc.’s stockholders equity has grown by 60.8% (from -$36.33 million to -$14.23 million).
- The most recent figure is from MiNK Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: